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The effect of procainamide and digoxin, singly and to-
gether, on peak active force and rate of force develop-
ment of isolated right ventricular papillary muscles from
adult cats was examined. Procainamide (1.5 x 1O-5M)
increased force and rate of force development in each
muscle with further increments in performance up to
2.4 x 1O- 4M in most muscles. The maximal increases
in force (±SEM) averaged 75 ± 13% above control
values. Essentially no response to procainamide was ob-
served when basal levels of contractile state were In-
creased by increasing stimulus frequency or calcium con-
centrations of the bathing solution. Propranolol (10- 6M)
markedly reduced and verapamil (I0 -7M) abolished the
Recently, we reported (I) that quinidine in concentrations
that are therapeutic in human patients had a variable ino-
tropic effect, but significantly inhibited the positive ino-
tropic action of digoxin in vitro . Procainamide and diso-
pyramide are grouped with quinidine as class I antiarrhythmic
agent s, yet it is well recognized that there are significant
differences among these drugs in their hemodynamic effects
(2-4) as well as their effect on serum digoxin levels (5). It
is generally accepted that disopyramide possesses negative
inotropic effects (4), but the effect of procainamide on
myocardial mechanical performance remain s in question
(2 ,3 ,6-9). Furthermore, to our knowledge there is no in-
format ion as to the effect of these latter agents on digitalis
inotropy . Accordingly , we examined the myocardial con-
tractile effects of procainamide and digoxin, singly and in
combination, using the method s we employed previously in
our quinidine-digoxin study (I ).
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inotropic effect of procalnamide, Exposing muscles to
procainamide (1.5 or 3 x IO-sM) before or after the
administration of digoxin (2 or 4 x 10-7M) did not alter
the inotropic action of either drug.
Thus, procainamide in concentrations that are in the
therapeutic range in human patients has potent positive
inotropic effects that may be masked at high levels of
contractile state. This action of procainamide appears
to be due to an effect on calcium channels, which in part
may be due to beta-adrenergic receptor stimulation. These
concentrations of procainaritide do not alter the inotropic
response to digoxin.
Methods
Preparation of papillary muscles. Right ventricular
papillary muscles were removed from anesthetized adult cats
and placed immediately in a muscle bath containing a so-
lution of the following cqncentration (roM): sodium 143,
potassium 4.5, magnesium 0.5 , calcium 1.25, chlorine
124, HzP04 - 1.2, HC03 24 and glucose 5.6. The solution
was bubbled vigorously with 95% oxygen and 5% carbon
dioxide , which produced a (Po-) partial pressure of oxygen
of greater than 500 mm Hg and a pH of 7.4. Temperature
was maintained at 30DC and the muscle was stimulated at
a frequency of 12/min using field electrodes parallel to the
long axis of the muscle . Stimulu s voltage was maintained
at 10% above threshold values and was checked frequentl y
during each experiment. The nontendinous end of the mus-
cle was held by a clip that was secured to the bottom of the
bath . The tendinous end was attached by a short silk suture
to a force transducer. The transducer was fixed to a mi-
crometer that permitted muscle length to be altered by known
amounts while the muscle contracted isometrically .
The muscle was stretched to 0.5 g of resting tension and
allowed to contract isometrically for 45 to 60 minute s, at
which time contractile force was stable . The muscle was
then stretched slowly until peak active force was obtained.
Muscle length was fixed at this point and peak active force
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and the maximal rate of force development (dF/dt) were
recorded, the latter determined electronically.
Studies with precainamide and digoxin. Muscles from
nine cats were exposed to increasing concentrations of pro-
cainamide ranging from 1.5 x 10- 5 to 2.4 x 1O-4M.
After each increment in concentration, adequate time was
allowed for contractile force to become stable before the
concentration was increased further. Seven additional mus-
cles were exposed to 1.5 x 10- 5M and another seven mus-
cles were exposed to 3 x 1O-5M procainamide, after which
each group was exposed to 2 x 1O-7M digoxin. After these
observations were made, the concentration of digoxin was
increased to 4 x 10- 7M in those muscles exposed initially
to 3 >: 1O-5M procainamide.
Thirteen muscles were exposed to digoxin alone initially
at a concentration of 2 x 10 7M, which subsequently was
increased to 4 x IO- 7M. Five additional muscles were
exposed initially to 4 x 10- 7M digoxin, followed by in-
creasing concentrations of procainamide. We selected these
digoxin concentrations on the basis of our earlier observation
that 2 < 1O-7M digoxin produced approximately half the
maximal inotropic effect obtainable with the glycoside,
whereas 4 x 10- 7M digoxin produced a near maximal
effect.
Procainamide studies after propranolol or verapa-
mil. After our observations on the effect of procainamide
alone, we exposed six muscles to lO- 6M propranolol and
then to increasing concentrations of procainamide, We also
exposed nine muscles to lO- 7M verapamil, followed by
increasing concentrations of procainamide.
Procainamide studies at higher stimulus frequency
and calcium concentration. In five other muscles, the fre-
quency of stimulation was increased from 12 to 30/min,
after which the muscles were exposed to increasing con-
centrations of procainamide. In seven muscles, the calcium
Table I. Developed Force with Various Interventions
concentration of the bathing solution was increased to 2.5
roM, and the studies with procainamide alone were repeated.
Procainamide was dissolved in distilled water. The mus-
cle bath contained 30 ml of modified Krebs solutions, and
the largest volume of procainamide-containing solution added
during any experiment was 1.28 ml.
Developed force and dF/dt were normalized for differ-
ences in muscle size by expressing these variables in units
per cross-sectional area. Cross-sectional area of the muscle
was determined from its weight wet and length at peak active
force development as measured with a calibrated reticle.
Statistical calculations. Statistical analyses were per-
formed using Student's paired and unpaired t test when
comparing respective values in individual animals or be-
tween groups, respectively. Analysis of variance was used
when comparing values among groups (10).
Results
Cross-sectional area of the muscles (mean ± standard
error of the mean) in the various groups averaged 1.2 ±
0.1 mm? (range 0.94 to 1.3). Differences among groups
were not statistically significant.
In all studies, changes in rate of force development were
quantitatively similar to the changes in developed force.
Therefore, We elected to present only the developed force
data.
Procainamide effect. The effect of increasing concen-
trations of procainamide on contractile force is given in
Table I. An increase in force occurred in each muscle ex-
posed to the lowest concentration of procainarnide (p <
0.01). In two muscles, force increased to a maximal value
at a procainamide concentration of 6 x 1O-5M , with no
further change up to a concentration of 2.4 x 1O-4M. In
five muscles, maximal values occurred at a concentration
Procainamide
Developed Force Control 1.5 X 10-',11 3.0 x 10 ',11 6.0 x 10 ',11 1.2 x 10- 4,11 2.4 x 10 4,11
Group A in = 9)
g/rnrrr' 1.9 ± 0.4 2.5 ± 0.5 2.6* ± 0.5 2.9* ± 0.5 3.1* ± 0.5 2.9* ± 0.5
% control 125 ± 4.3 142 ± 6.7 162 ± 10.5 175 ± 13.0 167 ± 14.0
Group B (n = 5)
g/rnrrr' 3.1 ± 0.4 3.2 ± 0.4 3.1 ± 0.4 3.0 ± 0.4 2.9 ± 0.4 2.7 ± 0.3
% control 102 ± 3.0 102 ± 7.1 96 ± 8.0 91 ± 10.0 88 ± 8.5
Group C In = 7)
g/mrn 4.6 ± 0.7 4.9 ± 0.7 5.0 ± 0.7 5.1 ± 0.6 5.1 ± 0.6 5.1 ± 0.7
% control 109 ± 0.8 112 ± 2.5 113 ± 3.2 114 ± 2.6 113 ± 3.9
Group D in = 5)
g/mm 2.5 ± 0.6 3.2* ± 0.7 3.8* ± 0.7 4.2* ± 0.6 4.0* ± 0.7 3.4 ± 0.8
% control 129 ± 2.0 158 ± 8.0 178 ± 19.5 172 ± 31.0 154 ± 42.0
*Values significantly different from control (p < 0.05). Data are reported as mean values ± standard error of the mean. Group A = procainarnide
at a stimulus frequency of 12/min; Group B = procainamide at a stimulus frequency of 30/min; Group C = procainamide with a calcium concentration
of 2.5 mM; Group D = procainamide after 4 x 10- 7,11 digoxin.
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Figure 2. Changes inpeakactiveforce produced by digoxin (DIG)
alone and after pretreatment with procainamide.
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Figure l. Effect of pretreatment with 10- 7M verapamil (Ver.)
(e--.) ot 1O - 6M propranolol (Prop.) (.--~.) on the force re-
sponse to procainamide. Cat muscles treated with procainamide
alone are represented by open circles. *Denotes values signifi-
cantly different (p < 0.05) from those with procainamide alone.
of 1.2 X 10 4M, with no further change at the highest
concentration. In the remaining two muscles, maximal val-
ues occurred at a procainarnide concentration of 1.2 x
1O-4M , with a decrease in function at 2.4 x 1O-4M. The
maximal increase in force averaged 75 ± 13% above control
values. Resting tension did not change at any concentration
of procainamide.
Procainamlde effect with increased calcium concen-
tration. Doubling the concentration of calcium in the bath-
ing solution to 2 .5 roM before the addition of procainamide
resulted in a marked increase in active force development
(Table I). Under these conditions, addition of procainamide
resulted in no significant increment in mechanical per-
formance ,
Procainamide effect at higher stimulus frequency.
Increasing stimulus frequency froin 12 to 30/min increased
developed force by an average of 57 ± 13%. Procainamide
then produced no increase in force (Table I).
Procainamide effect after propranolol or verapa-
mil. The positive inotropic effect of each concentration of
procainamide was significantly less after pretreatment with
1O-6M propranolol and was abolished by pretreatment with
1O - 7M verapamil (Fig. I).
Procainamide-digoxin interaction. The effect of 2 x
10- 7 and 4 x 1O-7M digoxin alone and after 1.5 X 10- 5
and 3 x 1O - 5M procainamide on active force development
is illustrated in Figure 2. Increments in force development
with digoxin after exposure to both conceritrations of pro-
cainamide were not significantl y different statistically from
that produced with digoxin alone. Pretreatment with 4 x
10 -7M digoxin also did not alter the positive inotropic re-
sponse to procainarnide (Table I).
Discussion
Comparison with previous studies. Our observation
that procainamide exerted a positive inotropic effect over a
wide range of concentrations is at variance with other studies
that have reported that procainamide has a negative (2,7)
or no (3,9) effect on myocardial mechanical performance .
However, others (6,8) reached conlcusions similar to ours.
A number of factors, such as the use of atrial versus
ventricular myocardium, intact anesthetized versus unan-
esthetized animals and human subjects, in vivo versus in
vitro studies as well as species differences may contribute
to these disparate results. Clearl y, the use of different con~
centrations of procainamide is an important variable and
high concentrations of the drug do produce negative ino-
tropic effect s as we observed in several muscles exposed to
2.4 x 1O - 4M procainamide .
Effect of basal contractile state on procainamide ino-
tropism. An additional factor that we believe contributes
to the variable response to procainamide is the level of
mechanical performance before drug exposure. When we
doubled the calcium concentration of our bathing solution,
active force development increased by approximately 130%
and procainamide then produced no significant increment
in force. Increasing force development by increasing stim-
ulus frequency also resulted in no inotropic response to
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procainamide. In muscles operating at increased levels of
contractile state, the inotropic action of procainamide may
not be apparent. However, there are exceptions as will now
be discussed,
Digoxin-procainamide interaction. Our results with a
near maximal concentration of digoxin and procainamide
demonstrate that neither drug alters the inotropic action of
the other. This implies that their inotropism is mediated by
different mechanisms. The latter implication is supported
by studies that demonstrated that procainamide does not alter
membrane sodium-potassium-adenosine triphophatase
(ATPase) activity (11), inhibition of which is believed to
result in the inotropic action of digitalis (12,13).
Mechanism of procainamide effects. The normal ino-
tropic response to procainamide after the contractile state
was increased by digoxin is unlike the blunted effect of
procainamide after increasing the contractile state by in-
creasing extracellular calcium or more rapid rates of stim-
ulation. The lack of inotropic effect of procainamide under
these Iarterconditions suggests a similar mechanism of ino-
tropic action, Increased extracellular calcium increases in-
tracellular calcium by directly enhancing slow channel in-
flux, The mechanism of action responsible for the force-
frequency effect is less clear, although increased slow chan-
nel influx may be involved (14),
Our observations with propranolol indicate that procain-
amide exerts at least part of its inotropic effect by stimulation
of beta-adrenergic receptors either directly or indirectly. OUf
results with verapamil are compatible with either a direct
effect of procainamide on slow channel influx or a beta-
adrenergic receptor agonist action. Others (15) demonstrated
that beta-adrenergic receptor stimulation augments slow
channel influx of calcium and that this effect and its ac-
companying increase in force development can be blocked
by calcium antagonists. An argument against the concept
that procainamide stimulates beta-adrenergic receptors is the
observation that concentrations of procainamide similar to
those we employed did not increase tissue cyclic adenosine
monophosphate (AMP) levels (16). However, these studies
were performed in atrial tissue.
Clinical implications. This study and our previous study
(1) indicate that procainamide possesses distinct advantages
over quinidine, but the clinical significance of these obser-
vations is conjectural. The concentrations of procainamide
used in the digoxin studies (4 and 8 j.Lg/ml) are well within
the therapeutic range for human beings and these concen-
trations did exert a positive inotropic effect albeit under
unphysiologic conditions, However, procainamide has
hemodynamic effects other than those due to its direct myo-
cardial action, and the former may modify the cardiac re-
sponse to the drug in vivo. Our study also was done using
normal muscles, and the response of depressed myocardium
may no! be similar. Furthermore, N-acetylprocainamide is
a major metabolite of procainamide and has significantly
different hemodynamic effects from those of its parent com-
pound (17,18), In any event, we have demonstrated that
drugs grouped together as class I antiarrhythmic agents on
the basis of their electrophysiologic effects have strikingly
different effects on mechanical performance and interact
differently with the cardiac glycosides.
We are indebted to Jeanne Arceneaux for expert assistance in the prepa-
ration of this manuscript.
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